Koers MiMedx Group Inc Nasdaq
Aandelen
US6024961012
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 357 mln. 334 mln. | Omzet 2025 * | 403 mln. 377 mln. | Marktkapitalisatie | 925 mln. 865 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 43 mln. 40,22 mln. | Nettowinst (verlies) 2025 * | 56 mln. 52,37 mln. | EV/omzet 2024 * | 2,59 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,29 x |
K/w-verhouding 2024 * |
20,4
x | K/w-verhouding 2025 * |
16,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,76% |
Recentste transcriptie over MiMedx Group Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 27-01-23 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 05-07-23 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 02-07-20 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 08-03-21 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-20,60% | 128 mln. | |
-7,82% | 67,46 mln. | |
+6,64% | 60,58 mln. | |
+14,87% | 61,68 mln. | |
+0,60% | 51,45 mln. |